XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.2
Supplemental Income Statement Information (Tables)
 6 Months Ended
Jun. 28, 2025
Supplemental Income Statement Elements [Abstract]  
Schedule of Disaggregated Revenues
Revenues by type are as follows:
Three months ended Six months ended
(In millions)June 28, 2025June 29, 2024June 28, 2025June 29, 2024
Revenues
Consumables
$4,606 $4,363 $8,960 $8,690 
Instruments
1,644 1,800 3,270 3,428 
Services
4,605 4,378 8,990 8,768 
Consolidated revenues$10,855 $10,541 $21,219 $20,886 
Revenues by geographic region based on customer location are as follows:
Three months endedSix months ended
(In millions)June 28, 2025June 29, 2024June 28, 2025June 29, 2024
Revenues
North America
$5,722 $5,529 $11,235 $11,048 
Europe
2,830 2,663 5,454 5,282 
Asia-Pacific
1,920 1,971 3,811 3,831 
Other regions
383 379 720 725 
Consolidated revenues$10,855 $10,541 $21,219 $20,886 
Revenues by business are as follows:
Three months endedSix months ended
(In millions)
June 28, 2025June 29, 2024June 28, 2025June 29, 2024
Revenues



Biosciences
$1,075 $1,059 $2,068 $2,118 
Genetic sciences
679 663 1,356 1,300 
BioProduction
745 633 1,416 1,223 
Life Sciences Solutions
2,499 2,355 4,840 4,640 
Chromatography and mass spectrometry
784 773 1,557 1,562 
Chemical analysis
292 324 578 644 
Electron microscopy
652 684 1,311 1,263 
Analytical Instruments
1,728 1,782 3,446 3,469 
Clinical diagnostics
276 273 539 536 
ImmunoDiagnostics
234 226 451 437 
Microbiology
159 158 311 312 
Transplant diagnostics
124 111 237 217 
Healthcare market channel
407 411 880 849 
Elimination of intrasegment revenues
(65)(62)(137)(125)
Specialty Diagnostics
1,134 1,117 2,282 2,227 
Laboratory products
601 639 1,183 1,264 
Research and safety market channel
1,883 1,775 3,610 3,486 
Pharma services
1,794 1,627 3,401 3,205 
Clinical research
1,955 1,949 3,894 3,982 
Elimination of intrasegment revenues and other
(238)(233)(453)(457)
Laboratory Products and Biopharma Services
5,995 5,758 11,635 11,480 
Elimination of intersegment revenues(501)(470)(983)(930)
Consolidated revenues$10,855 $10,541 $21,219 $20,886 
Schedule of Restructuring and Other Costs by Segment
Restructuring and other costs by segment are as follows:
Three months endedSix months ended
(In millions)June 28, 2025June 28, 2025
Life Sciences Solutions
$11 $54 
Analytical Instruments
10 14 
Specialty Diagnostics
3 5 
Laboratory Products and Biopharma Services
56 100 
Corporate
2 7 
$82 $180 
Schedule of Changes in the Company's Accrued Restructuring Balance
The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.
(In millions)Total (a)
Balance at December 31, 2024$50 
Net restructuring charges incurred in 2025 (b)
99 
Payments
(78)
Currency translation
4 
Balance at June 28, 2025$74 
(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b)Excludes $82 million of net charges, principally $67 million of charges for impairment of long-lived assets in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
Schedule of Earnings Per Share
The company’s earnings per share are as follows:
Three months endedSix months ended
June 28,June 29,June 28,June 29,
(In millions except per share amounts)2025202420252024
Net income attributable to Thermo Fisher Scientific Inc.$1,617 $1,548 $3,124 $2,875 
Basic weighted average shares378 382 378 382 
Plus effect of: stock options and restricted stock units— 1 1 1 
Diluted weighted average shares378 383 378 383 
Basic earnings per share$4.28 $4.05 $8.27 $7.53 
Diluted earnings per share$4.28 $4.04 $8.26 $7.50 
Antidilutive stock options excluded from diluted weighted average shares
4 2 3 2